Emerging data highlights the promise of metabolic peptides and hybrid agonists to transform therapeutic interventions for systemic diseases. These novel compounds offer the unique ability to simultaneously engage multiple pathways, circumventing the challenges of traditional mono-therapy treatments. By fine-tuning cellular signaling, they can impro